Caledonian and Pre-Caledonian orogenic events in Shetland, Scotland:evidence from garnet Lu-Hf and Sm-Nd geochronology

Garnet Lu-Hf and Sm-Nd ages from the Shetland Caledonides provide evidence of a pollorogenic history as follows: 1) c. 1050 Ma Grenvillian reworking of Neoarchaean basement; 2) c. 910 Ma Renlandian metamorphism of the Westing Group; 3) c. 622-606 Ma metamorphism of the Walls Metamorphic Series but of uncertain significance because the eastern margin of Laurentia is thought to have been in extension at that time; 4) Grampian I ophiolite obduction at c. 491 Ma followed by crustal thickening and metamorphism between c. 485 and c. 466 Ma; 5) Grampian II metamorphism between c. 458 and c. 442 Ma that appears to have been focused in areas here pre-existing foliations ere gentle-inclined and thus may have been relatively easily reworked; 6) Scandian metamorphism at c. 430 Ma, although the paucity of these ages suggests that much of Shetland did not attain temperatures for garnet growth. There is no significant difference in the timing of Caledonian orogenic events either side of the Walls Boundary Fault, although this need not preclude linkage with the Great Glen Fault. However, the incompatibility of Ediacaran events either side of the Walls Boundary Fault may indicate significant lateral displacement and requires further investigation

ENTOMOPHAGY Understanding New Zealand Consumers’ Attitudes Toward Eating Insects

While the ecological, economic, and social benefits of entomophagy are well documented, adoption of this food source in many Western countries has been slow. Understanding consumers’ attitudes towards entomophagy is important in determining if and how edible insects will be accepted as a food product in the future. This research determined the dominant discourses that exist towards entomophagy in New Zealand. Q methodology, which provides both a technique and philosophical principles for studying individuals’ judgments, attitudes, and points of view about a topic, was used to identify dominant consumer discourses. The objective of the study was to describe representations of different dominant participant viewpoints. Thirty-four participants living in Dunedin sorted a set of statements about entomophagy. The comparison of sorts across participants in a factor analysis enabled the identification of statistically similar participant viewpoints, which were then interpreted using the rich qualitative data obtained in interviews after card-sorting. Five different discourses were identified: ‘Enthusiastic adventurers’, ‘Benefit seekers’, ‘Disgusted disavowals’, ‘Tolerable but restrained’, and ‘Secure resolute’. In addition to practical insights about how insects could be positioned in the marketplace, the identification of these discourses adds to a limited literature on entomophagy attitudes. Future research that measures the prevalence of these discourses via a nation-wide representative survey would allow researchers to determine who holds these viewpoints, which would have useful implications for developing an insect industry

Realising the full potential of data-enabled trials in the UK : a call for action

Rationale: Clinical trials are the gold standard for testing interventions. COVID-19 has further raised their public profile, and emphasised the need to deliver better, faster, more efficient trials for patient benefit. Considerable overlap exists between data required for trials and data already collected routinely inelectronic healthcare records (EHR). Opportunities exist to utilise these in innovative ways to decrease duplication of effort, and speed trial recruitment, conduct and follow-up. Approach: The National Institute of Health Research (NIHR), Health Data Research UK (HDR UK) and Clinical Practice Research Datalink (CPRD) co-organised a national workshop to accelerate the agenda for “data-enabled clinical trials”. Showcasing successful examples and imagining future possibilities, the plenary talks, panel discussions, group discussions and case studies covered: design/feasibility; recruitment; conduct/follow-up; collecting benefits/harms; and analysis/interpretation. Reflection: Some notable studies have successfully accessed and used EHR to identify potential recruits, support randomised trials, deliver interventions and supplement/replace trial-specific follow-up. Some outcome measures are already reliably collected; others, like safety, need detailed work to meet regulatory reporting requirements. There is a clear need for system interoperability and a “route map” to identify and access the necessary datasets. Researchers running regulatory-facing trials must carefully consider how data quality and integrity would be assessed. An experience-sharing forum could stimulate wider adoption of EHR-based methods in trial design and execution. Discussion: EHR offer opportunities to better plan clinical trials, assess patients and capture data more efficiently, reducing research waste and increasing focus on each trial’s specific challenges. The short-term emphasis should be on facilitating patient recruitment and for post-marketing authorisation trials where research-relevant outcome measures are readily collectable. Sharing of case studies is encouraged. The workshop directly informed NIHR’s funding call. ambitious data-enabled trials at scale. There is the opportunity for the United Kingdom to build upon existing data science capabilities to identify, recruit and monitor patients in trials at scale

Finishing the euchromatic sequence of the human genome

The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead

ENTOMOPHAGY Understanding New Zealand Consumers’ Attitudes Toward Eating Insects

While the ecological, economic, and social benefits of entomophagy are well documented, adoption of this food source in many Western countries has been slow. Understanding consumers’ attitudes towards entomophagy is important in determining if and how edible insects will be accepted as a food product in the future. This research determined the dominant discourses that exist towards entomophagy in New Zealand. Q methodology, which provides both a technique and philosophical principles for studying individuals’ judgments, attitudes, and points of view about a topic, was used to identify dominant consumer discourses. The objective of the study was to describe representations of different dominant participant viewpoints. Thirty-four participants living in Dunedin sorted a set of statements about entomophagy. The comparison of sorts across participants in a factor analysis enabled the identification of statistically similar participant viewpoints, which were then interpreted using the rich qualitative data obtained in interviews after card-sorting. Five different discourses were identified: ‘Enthusiastic adventurers’, ‘Benefit seekers’, ‘Disgusted disavowals’, ‘Tolerable but restrained’, and ‘Secure resolute’. In addition to practical insights about how insects could be positioned in the marketplace, the identification of these discourses adds to a limited literature on entomophagy attitudes. Future research that measures the prevalence of these discourses via a nation-wide representative survey would allow researchers to determine who holds these viewpoints, which would have useful implications for developing an insect industry

Realising the full potential of data-enabled trials in the UK: a call for action.

RATIONALE: Clinical trials are the gold standard for testing interventions. COVID-19 has further raised their public profile and emphasised the need to deliver better, faster, more efficient trials for patient benefit. Considerable overlap exists between data required for trials and data already collected routinely in electronic healthcare records (EHRs). Opportunities exist to use these in innovative ways to decrease duplication of effort and speed trial recruitment, conduct and follow-up. APPROACH: The National Institute of Health Research (NIHR), Health Data Research UK and Clinical Practice Research Datalink co-organised a national workshop to accelerate the agenda for 'data-enabled clinical trials'. Showcasing successful examples and imagining future possibilities, the plenary talks, panel discussions, group discussions and case studies covered: design/feasibility; recruitment; conduct/follow-up; collecting benefits/harms; and analysis/interpretation. REFLECTION: Some notable studies have successfully accessed and used EHR to identify potential recruits, support randomised trials, deliver interventions and supplement/replace trial-specific follow-up. Some outcome measures are already reliably collected; others, like safety, need detailed work to meet regulatory reporting requirements. There is a clear need for system interoperability and a 'route map' to identify and access the necessary datasets. Researchers running regulatory-facing trials must carefully consider how data quality and integrity would be assessed. An experience-sharing forum could stimulate wider adoption of EHR-based methods in trial design and execution. DISCUSSION: EHR offer opportunities to better plan clinical trials, assess patients and capture data more efficiently, reducing research waste and increasing focus on each trial's specific challenges. The short-term emphasis should be on facilitating patient recruitment and for postmarketing authorisation trials where research-relevant outcome measures are readily collectable. Sharing of case studies is encouraged. The workshop directly informed NIHR's funding call for ambitious data-enabled trials at scale. There is the opportunity for the UK to build upon existing data science capabilities to identify, recruit and monitor patients in trials at scale.The workshop was co-funded by National Institute of Health Research (NIHR) Health Technology Assessment Programme, Clinical Practice Research Datalink (CPRD) and Health Data Research UK; MRC grant MC_UU_12023/24 funded the salary of Matthew Syde

Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort

Individuals with rare kidney diseases account for 5-10% of people with chronic kidney disease, but constitute more than 25% of patients receiving kidney replacement therapy. The National Registry of Rare Kidney Diseases (RaDaR) gathers longitudinal data from patients with these conditions, which we used to study disease progression and outcomes of death and kidney failure.People aged 0-96 years living with 28 types of rare kidney diseases were recruited from 108 UK renal care facilities. The primary outcomes were cumulative incidence of mortality and kidney failure in individuals with rare kidney diseases, which were calculated and compared with that of unselected patients with chronic kidney disease. Cumulative incidence and Kaplan-Meier survival estimates were calculated for the following outcomes: median age at kidney failure; median age at death; time from start of dialysis to death; and time from diagnosis to estimated glomerular filtration rate (eGFR) thresholds, allowing calculation of time from last eGFR of 75 mL/min per 1·73 m2 or more to first eGFR of less than 30 mL/min per 1·73 m2 (the therapeutic trial window).Between Jan 18, 2010, and July 25, 2022, 27 285 participants were recruited to RaDaR. Median follow-up time from diagnosis was 9·6 years (IQR 5·9-16·7). RaDaR participants had significantly higher 5-year cumulative incidence of kidney failure than 2·81 million UK patients with all-cause chronic kidney disease (28% vs 1%; p Background Methods Findings Interpretation Funding</p